Contributions and sources
A reference record for the projects: Dr. Meydan’s contribution to each study, its historical context, and the primary sources, with where in each source the information appears. For what each project studied and found, see the projects page.
The Meydan Lab at Weill Cornell Medicine studies lymphoma genomics, chromatin regulation, and spatial and single-cell biology. Methodological research develops machine-learning and statistical approaches for molecular data integration and biological modeling. Research also examines inflammatory and metabolic responses through host proteomics, spaceflight studies, and host–microbiome questions.
Dr. Meydan’s wider research record includes the NASA Twins Study, SOMA, mechanistic studies of enasidenib, rapid RT-LAMP testing and host-response research during New York’s first COVID-19 wave, and urban microbiome mapping. His entrepreneurial work includes GutBio development at Onegevity and research leadership at Thorne HealthTech. The linked study accounts retain individual contributions, historical context, sources, and resources.
A plain-text version and structured data carry the same content.
Chromatin remodeling and lymphoma
Nature, 2026 · Cancer Cell, 2024
Two linked studies examined the SWI/SNF (BAF) chromatin-remodeling complex. The 2024 Cancer Cell study showed how ARID1A loss reprograms B cells and exposes a therapeutic vulnerability in lymphoma. The 2026 Nature study showed how BAF disruption rewires CTCF binding and 3D genome organization across cancers.
Dr. Meydan led the computational analyses and data curation of the 2026 study and supervised its computational and statistical work. He shares first and corresponding authorship on that paper. On the 2024 study he shares first authorship and is credited with formal analysis and investigation. He is a named co-inventor on the international patent application that followed from the 2024 study.
SWI/SNF, CTCF, and the 3D genome
DOI: 10.1038/s41586-026-11197-w
- Findings
- The study connected BAF disruption with altered CTCF binding, 3D genome organization, and cancer-associated gene regulation.
- Dr. Meydan’s contribution
- Led the computational analyses and data curation, and supervised the computational and statistical work.
Dr. Meydan’s contributions also included visualization and manuscript review. Sonia Debek, Cem Meydan, and Christopher Chin share first authorship. Ari Melnick, Darko Barisic, and Cem Meydan share corresponding authorship.
Experimental therapeutic implications remain tied to the study’s model systems.
Code, data and access
| Type | Resource |
|---|---|
| Code | Nature 2026 analysis code (meydan-lab) |
| Code | Multiome processing code (crchin) |
| Public data | GEO GSE294051 |
| Public data | GEO GSE237990 |
Sources
| Topic | Source | Where | Notes |
|---|---|---|---|
| Finding and authorship | Debek, Meydan, Chin et al., Nature Nature, 2026 | Author contributions | The study’s findings and shared first and corresponding authorship. The contribution statement reads: “C. Meydan led the computational analyses and data curation.” |
| Institutional summary | A unifying mechanism for cancer-driving mutations Weill Cornell Medicine, October 2026 | Institutional account of the study. | |
| Analysis code | Nature_2026_BAF_CTCF GitHub (meydan-lab) | Transcription-factor regulatory-potential and chromatin-model analysis code. | |
| Processing code | multiome_process GitHub (crchin) | Multiome processing code. | |
| Data | GSE294051 and GSE237990 NCBI GEO | Accessions linked from the paper. |
About these sources. The paper documents the findings, shared first and corresponding authorship, and that Dr. Meydan led the computational analyses and data curation.
ARID1A loss in lymphoma: mechanism and therapeutic vulnerability
DOI: 10.1016/j.ccell.2024.02.010
- Findings
- The study linked ARID1A loss and altered B-cell fate to a vulnerability to SMARCA2/SMARCA4 inhibition. The work led to an international patent application for the use of these inhibitors in lymphoma.
- Dr. Meydan’s contribution
- Formal analysis and investigation; named co-inventor on the resulting patent application.
The international application WO 2025/096976 A1 was published on May 8, 2025. The published inventors are Darko Barisic, Ari Melnick, Christopher Chin, and Cem Meydan. The applicant is Cornell University.
Code, data and access
| Type | Resource |
|---|---|
| Code | Study analysis code (melnick-lab) |
| Public data | GEO GSE237990 |
Sources
| Topic | Source | Where | Notes |
|---|---|---|---|
| Finding and authorship | Barisic, Chin, Meydan et al., Cancer Cell Cancer Cell, 2024 | Author contributions | The study’s findings and listed contributions. |
| Inventorship and application | WO2025096976A1 WIPO, published May 8, 2025 | Inventors | Named inventors and the published international application. |
| Analysis code | Barisic_et_al_CancerCell_2024 GitHub (melnick-lab) | Study analysis code. | |
| Data | GSE237990 NCBI GEO | Study data accession. |
About these sources. The paper documents the findings and Dr. Meydan’s listed contributions. The patent record lists the named inventors and the published international application.
An integrated view of human spaceflight
Science, 2019 · Cell, 2020 · Nature, 2024
The NASA Twins Study combined molecular, physiological, and cognitive measurements before, during, and after a year-long spaceflight. An identical twin on Earth provided a genetically matched comparison. NASA described it as the first integrated biomolecular view of the human response to spaceflight. Dr. Meydan shares first authorship and contributed transcriptomic and integrative-analysis methods.
The 2020 Cell study integrated astronaut profiles with experimental-model data and identified mitochondrial stress as a central biological response to spaceflight. Dr. Meydan shares first authorship and analyzed its DNA methylation data.
SOMA, the Space Omics and Medical Atlas (Nature, 2024), connected molecular and clinical measurements across missions and combined a shared research resource with an international astronaut biobank. Dr. Meydan shares corresponding authorship; his contributions include methodology, formal analysis, investigation, and visualization, and he supervised computational and statistical work. A companion study records that he co-led the Inspiration4 and Twins data acquisition and sharing.
Together, the studies moved from integrated measurement of one mission, to a biological synthesis across astronauts and model organisms, to shared data infrastructure. The work spans longitudinal, single-cell, and multiomic measurements of immune changes, mitochondrial stress, and host–microbiome responses.
Further sources: NASA’s 2019 account of the Twins Study.
NASA Twins Study
- Findings
- The NASA Twins Study compared a year-long spaceflight with an identical-twin ground control. It integrated molecular and physiological measurements across the mission.
- Dr. Meydan’s contribution
- Transcriptomic and integrative-analysis methods, formal analysis, and manuscript development.
The NASA Twins Study was a multi-institution NASA program. Dr. Meydan’s role was within that collaboration. Human research data are available by request through the NASA Life Sciences Portal. They are not an open download.
Code, data and access
| Type | Resource |
|---|---|
| Controlled data (request access) | NASA Life Sciences Portal data requests |
| Paper | Author manuscript (PMC) |
Sources
| Topic | Source | Where | Notes |
|---|---|---|---|
| Study and authorship | Garrett-Bakelman et al., The NASA Twins Study Science, 2019 | The study and its authorship. | |
| Author manuscript | NASA Twins Study (PMC) PubMed Central | Author contributions | Open author manuscript and contribution list. |
| Data leadership | Wu, Du, Overbey et al., Single-cell analysis identifies conserved features of immune dysfunction in simulated microgravity and spaceflight Nature Communications, 2024 | Author contributions | “C.M., C.E.M., F.G-B., and A.B. led Twins study data acquisition and sharing.” |
| Data access | Data request FAQ NASA Life Sciences Portal | Request route for controlled human data. |
About these sources. The paper and its author manuscript document the study, the shared first authorship, and the listed contributions. A later study documents his co-leadership of the Twins data acquisition and sharing.
Mitochondrial stress during spaceflight
- Findings
- This study integrated astronaut profiles with experimental-model data. The findings identified mitochondrial stress as a central biological response to spaceflight.
- Dr. Meydan’s contribution
- Analyzed DNA methylation data.
WGCNA code is provided in the article’s Methods S1 supplement. Study metabolomics are at OSD-343 (formerly GLDS-343). The article’s Key Resources Table lists the additional GeneLab datasets it reuses.
Code, data and access
| Type | Resource |
|---|---|
| Public data | OSD-343 · study metabolomics |
| Paper | Open article and supplements (PMC) |
Sources
| Topic | Source | Where | Notes |
|---|---|---|---|
| Study and authorship | da Silveira et al., Comprehensive Multi-Omics Analysis Reveals Mitochondrial Stress as a Central Biological Hub for Spaceflight Impact Cell, 2020 | Author contributions | The study, shared first authorship, and listed contributions. |
| Data | OSD-343 NASA Open Science Data Repository | Study metabolomics. |
About these sources. The paper documents the study, the shared first authorship, and the listed contributions.
SOMA: spaceflight data and research infrastructure
DOI: 10.1038/s41586-024-07639-y
- Findings
- The Space Omics and Medical Atlas connects molecular and clinical measurements across space missions. SOMA combines a shared research resource with an international astronaut biobank.
- Dr. Meydan’s contribution
- Methodology, formal analysis, investigation, and visualization; supervised computational and statistical work.
SOMA is a collaborative consortium resource. Dr. Meydan shares corresponding authorship. A companion study in the Inspiration4 package lists him among those who led Inspiration4 data acquisition and sharing, and NASA Twins Study data acquisition and sharing. His supervision refers to computational and statistical work in these studies, not to oversight of the whole consortium or biobank.
Code, data and access
| Type | Resource |
|---|---|
| Portal | SOMA resource |
| Portal | SOMA Browser |
| Portal | PBMC Multiome Browser |
| Portal | Inspiration4 Microbiome Browser |
| Code | Inspiration4 study code |
| Index | SOMA dataset and code index (Nature) |
| Public data | OSD-574 · skin biopsies |
| Public data | OSD-630 · stool |
| Public data | OSD-572 · crew swabs |
| Public data | OSD-573 · capsule swabs |
| Public data | OSD-575 · blood serum |
| Public data | OSD-656 · urine |
| Biospecimen request | CAMbank: Cornell Aerospace Medicine Biobank |
Sources
| Topic | Source | Where | Notes |
|---|---|---|---|
| Resource and authorship | Space Omics and Medical Atlas Nature, 2024 | Author contributions | The resource, shared corresponding authorship, and listed contributions (methodology, formal analysis, investigation, visualization, review and editing). |
| Data leadership | Wu, Du, Overbey et al., Single-cell analysis identifies conserved features of immune dysfunction in simulated microgravity and spaceflight Nature Communications, 2024 | Author contributions | “E.O., C.M., J.K., and C.E.M. led I4 data acquisition and sharing. C.M., C.E.M., F.G-B., and A.B. led Twins study data acquisition and sharing.” |
| Resource access | SOMA Weill Cornell Medicine | Portal landing page and browsers. | |
| Code and data | SOMA dataset and code index Nature collection | Canonical index of SOMA datasets and code. |
About these sources. The paper documents the resource, the shared corresponding authorship, and the listed contributions. A companion Inspiration4 study documents his co-leadership of the mission’s data acquisition and sharing.
Targeted therapy in acute myeloid leukemia
Preclinical studies, 2014–2017 · First IDH2 inhibitor approved, 2017
Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow; some cases carry mutations in IDH2. Preclinical studies linked mutant IDH2 inhibition to reduced abnormal DNA methylation and restored differentiation in leukemia models. The first enasidenib clinical report cited the 2014 AG-221 findings of Shih, Shank, Meydan and colleagues. A clinical-mechanism study cited both the 2014 work and the 2017 Cancer Discovery paper.
Dr. Meydan shares first authorship on the 2017 paper. He contributed methodology and the computational analysis and interpretation of the epigenomic data. The FDA approved enasidenib in August 2017. The documented connection is the preclinical mechanism and its citation in the original clinical-development literature.
IDH2 inhibition: epigenomic evidence for a targeted leukemia therapy
DOI: 10.1158/2159-8290.CD-16-1049
- Findings
- Preclinical studies linked mutant IDH2 inhibition to reduced abnormal DNA methylation and restored differentiation in leukemia models. The first enasidenib clinical report cited the 2014 AG-221 findings. A clinical-mechanism study cited both the 2014 and 2017 work.
- Dr. Meydan’s contribution
- Methodology development, computational analysis and interpretation of epigenomic data, and manuscript writing.
Drug milestone: FDA approval · 2017
The initial enasidenib clinical report cites the 2014 AG-221 findings of Shih, Shank, Meydan and colleagues. The clinical-mechanism study also cites the 2017 Cancer Discovery paper by Shih, Meydan and colleagues. The 2017 paper’s Authors’ Contributions list C. Meydan under development of methodology; analysis and interpretation of data (statistical and computational analysis); writing, review, and revision of the manuscript; and administrative, technical, or material support (organizing data, constructing databases).
Sources
| Topic | Source | Where | Notes |
|---|---|---|---|
| Mechanistic and epigenomic findings | Shih, Meydan et al., combination targeted therapy in IDH2- and TET2-mutant AML Cancer Discovery, 2017 | Authors’ Contributions | Preclinical findings, shared first authorship, and the contribution record: methodology; analysis and interpretation of data; writing, review, and revision; administrative, technical, or material support. |
| Author manuscript | Shih, Meydan et al. (PMC) PubMed Central | Open author manuscript of the 2017 paper. | |
| Connection to the initial clinical report | Stein et al., Enasidenib in mutant IDH2 relapsed or refractory AML Blood, 2017 | Reference 19 | Cites the 2014 AG-221 findings of Shih, Shank, Meydan and colleagues. |
| Connection to clinical-mechanism work | Amatangelo et al., Enasidenib induces AML differentiation Blood, 2017 | References 15 and 17 | Cites the earlier AG-221 work and the 2017 mechanistic paper. |
| Approval of enasidenib | FDA approves new targeted treatment for relapsed or refractory AML U.S. FDA, August 1, 2017 | The drug’s approval milestone. Not a record of individual contributions. |
Regulatory context
- FDA approval package · NDA 209606. Approval documents for enasidenib.
- FDA correspondence · PDF page 195. An FDA request for an in-vitro DNA-hypermethylation reversal study.
- FDA multidisciplinary review. The agency’s review of the application.
About these sources. These records document the scientific and clinical-publication connection.
COVID-19 in New York: testing, viral genomics and host response
2020–2022 · Nature Medicine · Nature Communications · Nature · Cell Reports Medicine
New York’s first COVID-19 wave created an urgent need for testing and molecular information. Clinical laboratories faced backlogs and shortages of PCR reagents. Fully at-home self-testing was not yet available in the United States.
Rapid PCR instruments could shorten laboratory turnaround, but they still required dedicated equipment. RT-LAMP offered a different route to expanding molecular testing. The amplification reaction ran at a constant temperature and produced a visible color change in about 30 minutes. It reduced the instrumentation needed for detection and offered an alternative to constrained PCR workflows.
The study combined RT-LAMP testing with viral sequencing, host-response profiling, and spatial measurements. Clinical specimens from 669 patients were collected during the first months of New York’s outbreak. The work characterized viral lineages and host responses and provided molecular data for further research. Dr. Meydan shares first authorship. His contributions included assay validation and genetic and statistical analyses.
The assay was developed through a collaboration involving Weill Cornell Medicine, Color, and New England Biolabs. The validation results contributed to the evidence supporting Color’s FDA emergency authorization in May 2020. The study was published in Nature Communications in March 2021.
Subsequent studies examined multi-organ transcriptional disruption, loss of tissue identity, lung inflammation and repair, and molecular associations with severe outcomes. Together, these studies addressed urgent questions about detection, viral variation, and host injury during the pandemic.
Low-infrastructure diagnostic platforms
TINY, developed by the Erickson and Cesarman teams, illustrates the broader potential of isothermal diagnostics in resource-limited settings. Its thermal system can use sunlight, a flame, or electricity and store heat through power interruptions. Earlier field testing in Uganda concerned Kaposi sarcoma-associated herpesvirus. Mozsary and colleagues subsequently evaluated SARS-CoV-2 testing on the platform.
Sources: Snodgrass et al., Nature Biomedical Engineering, 2018 · Cornell Chronicle, September 11, 2018 · Mozsary et al., 2021 (PubMed Central) · PubMed record.
Historical context: Cepheid emergency authorization announcement, March 21, 2020 · FDA: first fully at-home self-test, November 17, 2020 · FDA: first over-the-counter fully at-home test, December 15, 2020 · Weill Cornell’s early COVID-19 testing program.
Related studies
- A diagnostic host response biosignature for COVID-19 from RNA profiling of nasal swabs and blood Science Advances, 2021
- Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts Science Translational Medicine, 2023
Rapid RT-LAMP testing and SARS-CoV-2 tracking in New York
DOI: 10.1038/s41467-021-21361-7
- Findings
- The study combined RT-LAMP testing with viral sequencing, host-response profiling, and spatial measurements across clinical specimens from New York’s first wave. The sequencing tracked the lineage that dominated New York’s early outbreak. The validation results contributed to the evidence supporting Color’s FDA emergency authorization in May 2020.
- Dr. Meydan’s contribution
- Helped design the RT-LAMP protocol and primers, and validated the test statistically against RT-PCR, shotgun sequencing, and clinical health records; performed genetic and statistical analyses.
The study combined viral sequencing, host gene-expression analysis, and rapid testing across clinical samples from New York. The RT-LAMP validation used RT-PCR as a comparator. The collaboration included Weill Cornell Medicine, Color, and New England Biolabs.
The broader study profiled 669 unique patients. The RT-LAMP validation used a separate set of 201 samples.
The emergency authorization is a historical milestone for the assay.
Code, data and access
| Type | Resource |
|---|---|
| Portal | COVID Genes (host and viral expression) |
| Controlled data (request access) | dbGaP phs002258.v1.p1 (paper-cited version) |
| Public data | Viral genomes MW493710–MW493863 (GenBank) |
Sources
| Topic | Source | Where | Notes |
|---|---|---|---|
| Study, assay and authorship | Butler, Mozsary, Meydan et al., Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 Nature Communications, 2021 | The study, the RT-LAMP validation, and shared first authorship. | |
| Assay collaboration and authorization | Researchers create rapid diagnostic tests and multi-omics analytics platforms for SARS-CoV-2 Weill Cornell Medicine, March 2021 | Institutional account of the collaboration and Color’s authorization. | |
| Press account of his role | New coronavirus test gives results in 30 minutes (in Turkish) The Independent (Turkish edition), 2020 | Names Dr. Meydan of Weill Cornell Medicine as working on the LAMP test. An archived copy is in the media section. | |
| Emergency authorization | Color authorization letter U.S. FDA, May 2020 | The assay’s historical emergency authorization. | |
| Data | dbGaP phs002258.v1.p1 NCBI dbGaP | Controlled-access sequencing and specimen metadata. The record points to a newer version. |
About these sources. The paper and the institutional account document the assay, the sequencing, and the collaboration, and the paper records his shared first authorship. Its contribution statement credits other authors with the wet-lab LAMP experiments. A 2020 Independent Türkçe report quotes him as working on the LAMP test.
System-wide tissue damage in COVID-19
Paper: System-wide transcriptome damage and tissue identity loss in COVID-19 patients
- Findings
- Autopsy and nasopharyngeal profiling showed that COVID-19 disrupts transcriptional programs and tissue identity across many organs. In the lung, these changes tracked viral load and disease stage.
- Dr. Meydan’s contribution
- Performed RNA-seq bioinformatics analyses and statistical investigations.
Code, data and access
| Type | Resource |
|---|---|
| Portal | COVID Genes (autopsy and swab expression) |
Sources
| Topic | Source | Where | Notes |
|---|---|---|---|
| Findings, authorship and contribution | Park, Foox, Hether et al., System-wide transcriptome damage and tissue identity loss in COVID-19 patients Cell Reports Medicine, 2022 | Author contributions | Corresponding authorship and RNA-seq bioinformatics and statistical analyses. |
About these sources. The paper documents the findings, the shared corresponding authorship, and the listed contributions.
Host response and severe COVID-19 outcomes
DOI: 10.1038/s41591-020-1021-2
- Findings
- Health records and nasal-swab transcriptomes linked complement and coagulation activation to ventilation and death (Nature Medicine). Spatial profiling of autopsy lungs mapped infected alveolar cells and the inflammation and repair that followed (Nature).
- Dr. Meydan’s contribution
- Collected and organized data and contributed to data analysis (Nature Medicine). Contributed to the digital spatial transcriptomics (Nature).
Sources
| Topic | Source | Where | Notes |
|---|---|---|---|
| Complement and coagulation findings; contribution | Ramlall, Thangaraj, Meydan et al., Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection Nature Medicine, 2020 | Author contributions | Data collection and organization, and data analysis. |
| Lung pathology findings; contribution | Rendeiro, Ravichandran, Bram et al., The spatial landscape of lung pathology during COVID-19 progression Nature, 2021 | Author contributions | Contributions to the digital spatial transcriptomics. |
About these sources. Each paper’s author-contribution statement lists these roles.
Urban microbiome mapping
Cell Systems, 2015 · Cell, 2021
PathoMap produced the first city-scale DNA map of a subway system, sampling all 466 open New York stations. It made the front page of The Wall Street Journal and led to the global MetaSUB consortium. Dr. Meydan shares first authorship on the 2015 Cell Systems study.
The International MetaSUB Consortium’s global atlas of urban microbiomes and antimicrobial resistance covered 60 cities (Cell, 2021). The MetaSUB Map portal credits Cem Meydan and David Danko, and the StuckOnU 2017 page credits its website and visualizations to Dr. Meydan. This is earlier research; the lab’s current host–microbiome questions are part of its inflammation and metabolism research.
Papers
- Geospatial Resolution of Human and Bacterial Diversity with City-Scale Metagenomics Cell Systems, 2015
- Global Genetic Cartography of Urban Metagenomes and Anti-Microbial Resistance Cell, 2021
Ventures: entrepreneurship and product development
Dr. Cem Meydan’s company work. The companies are separate from the Meydan Lab and Weill Cornell Medicine.
Dr. Meydan’s ventures span microbiome product development and data-driven approaches to human performance. Dr. Meydan joined Onegevity as a founding employee and built the GutBio product and analytical platform. He continued research and microbiome product leadership at Thorne HealthTech through its IPO and subsequent acquisition. He is also a co-founder of ARQ.
Onegevity → Thorne HealthTech
Dr. Meydan’s role: Founding employee · GutBio product and research leadership
Dr. Meydan joined Onegevity as a founding employee and built the GutBio product and analytical platform from the ground up. He continued to lead research and microbiome product development at Thorne HealthTech after the merger. His work spanned the company’s 2021 IPO and its 2023 acquisition by L Catterton. GutBio supported commercial microbiome testing in the United States and Japan.
Dr. Meydan’s responsibilities spanned the original product build, microbiome analytics, and continued research leadership after the merger. He also shares first authorship on a metagenome-guided intervention study. Thorne HealthTech cited that research in the Gut Health Test section of its IPO registration statement.
Company milestones
- 2021 Onegevity and Thorne merge and form Thorne HealthTech.
- 2021 Thorne HealthTech completes its IPO on Nasdaq.
- 2023 L Catterton acquires Thorne HealthTech.
Research from this work
- Metagenome-guided interventions in IBS Precision Clinical Medicine, 2020
- Wipe-based stool collection and preservation kit Frontiers in Immunology, 2022
- Multiomic profiling of breast cancer survivors Metabolites, 2024
- Personalized high-altitude protocols and hematologic health Heliyon, 2024
- Multi-omic study of women with PCOS Precision Clinical Medicine, 2025
Sources
| Source | Notes |
|---|---|
| Metagenome-guided intervention study Precision Clinical Medicine, 2020 | The study, Dr. Meydan’s shared first authorship, and his author affiliation: Onegevity Health, New York. |
| Wipe-based stool collection and preservation kit Frontiers in Immunology, 2022 | Dr. Meydan’s author affiliation is Thorne HealthTech. The same affiliation appears on the high-altitude case study (Heliyon, 2024) and the PCOS study (Precision Clinical Medicine, 2025), and Thorne Research on the breast cancer survivors atlas (Metabolites, 2024); all are listed under the research above. |
| Nathan Price, Thorne chief science officer: “Microbiome: Mastering the Market” Naturally Informed, June 2024 (slides) | The acknowledgements credit “Cem Meydan, Ph.D., Scientific Researcher, Thorne HealthTech”. A Thorne Gut Health Test slide presents the IBS intervention results and cites Meydan C, et al., Precis Clin Med 2020. |
| Nathan Price, Thorne chief science officer, conference slides Naturally Informed, May 2023 (slides) | The same acknowledgement and IBS-study slide. |
| Nathan Price: “Future of the Microbiome” Future of the Microbiome, December 2022 (slides) | The same acknowledgement of Dr. Meydan at Thorne HealthTech. |
| Loukia Lili, former Thorne HealthTech senior director of bioinformatics: high-altitude tent study write-up Personal blog, May 2022 | Lists “Cem Meydan, PhD – Principal bioinformatician, Thorne HealthTech Inc., study co-lead”. The study was later published in Heliyon (2024). |
| Thorne HealthTech IPO registration statement SEC, September 2021 | Business section, “Gut Health Test” (prospectus p. 113): describes the 88-participant IBS intervention study and cites “Meydan C, et al. Improved gastrointestinal health for irritable bowel syndrome with metagenome-guided interventions. Precis Clin Med. 2020”. |
| Space Omics and Medical Atlas, competing interests Nature, 2024 | The competing-interests statement records Dr. Meydan’s compensation by Thorne HealthTech. |
| Thorne merges with Onegevity Thorne, 2021 | The merger and the new parent company. |
| L Catterton completes acquisition of Thorne HealthTech Thorne, 2023 | The acquisition. |
| Japan testing agreement SEC quarterly filing, June 2023 | Commercial testing in Japan. |
| Kirin MicroBio Me launch Kirin Holdings, July 2023 | The Japanese consumer launch. |
| Thorne 2022 annual report SEC, 2023 | IPO history. |
Related work: Onegevity and Thorne filed sample-collection patent applications for a wipe-based kit (US 2021/0282389 A1, JP 2024-071621 A). Dr. Meydan coauthored the related wipe-kit study.
About these sources. Author affiliations document Dr. Meydan at Onegevity Health (2020) and at Thorne HealthTech and Thorne Research (2022–2025). The IPO registration statement and Thorne’s chief science officer’s conference slides (2023–2024) cite his IBS study as the evidence behind the Gut Health Test, and the officer’s slides (2022–2024), a former colleague’s study write-up, and published competing-interest statements record his Thorne HealthTech role. Corporate filings and announcements document the merger, IPO, acquisition, and Japanese commercialization. Onegevity’s own team pages went offline after the merger, so his founding-employee timing and day-to-day product-build responsibilities are his own account. The companies are separate from the Meydan Lab and Weill Cornell Medicine.
ARQ
Dr. Meydan’s role: Co-founder
Dr. Meydan is a co-founder of ARQ. The company develops data-driven approaches to human performance. onearq.com
Research resources
Portals, biobanks and maps from studies Dr. Meydan coauthored, with their access conditions and credits.
| Resource | Purpose | Years | Type | Access | Related study |
|---|---|---|---|---|---|
| SOMA | Space Omics and Medical Atlas landing page and linked study resources. | 2024– | Consortium resource | Open portal | SOMA: spaceflight data and research infrastructure |
| SOMA Browser | Browse multiomic data from Inspiration4, Polaris Dawn, Axiom and control participants. | 2024– | Interactive portal | Open portal | SOMA: spaceflight data and research infrastructure |
| PBMC Multiome Browser | Explore single-cell multiome data from Inspiration4 blood samples. | 2024– | Interactive portal | Open portal | SOMA: spaceflight data and research infrastructure |
| Inspiration4 Microbiome Browser | Explore microbiome data from the Inspiration4 crew and capsule. | 2024– | Interactive portal | Open portal | SOMA: spaceflight data and research infrastructure |
| CAMbank | Cornell Aerospace Medicine Biobank of spaceflight specimens. | 2024– | Biospecimen resource | Sample requests by proposal | SOMA: spaceflight data and research infrastructure |
| COVID Genes | Explore host and viral gene expression in SARS-CoV-2 infection. | 2020– | Research portal | Open portal | Rapid RT-LAMP testing and SARS-CoV-2 tracking in New York |
| MetaSUB Map | Urban microbiome sampling and visualization. The portal credits Cem Meydan and David Danko. | 2016– | Consortium resource | Open portal | |
| StuckOnU 2017 | Visualization of a 48-hour phone-swabbing experiment. The page credits the website and visualizations to Cem Meydan. | 2017 | Historical visualization | Open page | |
| PathoMap | New York City subway microbiome map (2015). | 2015 | Historical resource | Availability varies |
Study code and data indexes
- Nature 2026 analysis code (meydan-lab) (Code; SWI/SNF, CTCF, and the 3D genome)
- Multiome processing code (crchin) (Code; SWI/SNF, CTCF, and the 3D genome)
- Study analysis code (melnick-lab) (Code; ARID1A loss in lymphoma: mechanism and therapeutic vulnerability)
- Inspiration4 study code (Code; SOMA: spaceflight data and research infrastructure)
- SOMA dataset and code index (Nature) (Index; SOMA: spaceflight data and research infrastructure)
Content reviewed 2026-10-31.